Abstract Clinical evidence supports the notion that T cell exhaustion and terminal differentiation pose challenges to the persistence and effectiveness of chimeric antigen receptor-T (CAR-T) cells. MEK1/2 inhibitors (MEKIs). widely used in cancer treatment due to their ability to inhibit aberrant MAPK signaling. have shown potential synergistic effects when combined with immunotherapy. https://thecookiecountesses.shop/product-category/gel-color/